World trends of incidence of gynecologic malignancies in young women

Although cervical, ovarian, and uterine cancers are rare in young women, they may cause symptoms and physical disability, and the cancer treatment may also result in psychological stress, infertility, and iatrogenic menopause. While the incidence of cervical cancer appears to be decreasing, the incidences of ovarian and uterine cancers are increasing in young women. A thorough knowledge of the epidemiology of these cancers is important to help clinicians to understand the cost-effectiveness and outcomes of the screening and treatment strategies, and to help the policy makers to have a more accurate prediction of the disease load for better allocation of health resources. A more structured and detailed data collection system is needed so that the epidemiologic characteristics of these cancers can be better studied across different countries and age groups.

Cervical; Ovarian; Uterine; Cancers; Young women.

[1] International Agency for Research on Cancer: “Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 Lyon, France: World Health Organization, 2014”. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

[2] International Agency for Research on Cancer: “World Cancer Report 2008”. Lyon, France: World Health Organization, 2008.

[3] CI5: “Cancer Incidence in five Continents”. World Health Organization, 2014. Available at: http://ci5.iarc.fr/Default.aspx.

[4] Denny L., Quinn M., Hacker N.: “FIGO Cancer Report 2012”. Int. J. Gynaecol. Obstet., 2012, 119, S89.

[5] Cancer Research UK: “Cancer Stats: Cancer Statistics for the UK London, United Kingdom, 2014”. Available from: http://www.cancerresearchuk. org/cancer-info/cancerstats/keyfacts/cervicalcancer/

[6] Australian Institute of Health and Welfare (AIHW): Australian Cancer Incidence and Mortality (ACIM) books: Cervical cancer. Canberra, Australia: AIHW, 2014”. Available at: http://www.aihw.gov.au/acim-books.

[7] Surveillance, Epidemiology, and End Results Program: “Cancer Stat Fact Sheets Bethesda, USA: National Cancer Institute 2014”. Available at: http://seer.cancer.gov/canstat/animator/.

[8] The NORDCAN group: “Cancer stat fact sheets Copenhagen, Denmark: Association of the Nordic Cancer Registries, 2014”. Available at: http://www-dep.iarc.fr/NORDCAN/english/frame.asp.

[9] Quinn M.A., Benedet J.L., Odicino F., Maisonneuve P., Beller U., Creasman W.T., et al.: “Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer”. Int. J .Gynaecol. Obstet., 2006, 95, S43.

[10] Howlader N.N.A., Krapcho M., Garshell J., Miller D., Altekruse S.F., Kosary C.L., et al. (eds). SEER Cancer Statistics Review, 1975-2011. Bethesda, MD, USA: National Cancer Institute, Apr 2014. Available at: http://seer.cancer.gov/csr/1975_2011/.

[11] Australian Institute of Health and Welfare & Australasian Association of Cancer Registries 2012. Cancer in Australia: an overview. Canberra: AIHW, 2012.

[12] Hong Kong Cancer Registry, Cancer facts: “Hospital Authority 2014”. Available at: http://www3.ha.org.hk/cancereg/Statistics.html-cancerfacts.

[13] Patel A., Galaal K., Burnley C., Faulkner K., Martin-Hirsch P., Bland M.J., et al.: “Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study”. Br. J. Cancer, 2012, 106, 1753.

[14] Center for Cancer Control and Information Services N.C.C.: “National estimates of cancer incidence based on cancer registries in Japan (1975-2010)”. Japan 2014.. Available at: http://ganjoho.jp/en/professional/statistics/table_download.html.

[15] Foley G., Alston R., Geraci M., Brabin L., Kitchener H., Birch J.: “Increasing rates of cervical cancer in young women in England: an analysis of national data 1982-2006”. Br. J. Cancer, 2011, 105, 177.

[16] National Cancer Intelligence Network (NCIN): “Cervical cancer incidence and screening coverage”. London, United Kingdom: National Cancer Intelligence Network (NCIN), 2011.

[17] Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al.: “Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial”. Lancet, 2007, 369, 2161.

[18] Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsague X., et al.: “Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial”. Lancet Oncol., 2012, 13, 89.

[19] Ferris D., Samakoses R., Block S.L., Lazcano-Ponce E., Restrepo J.A., Reisinger K.S., et al.: “Long-term Study of a Quadrivalent Human Papillomavirus Vaccine”. Pediatrics, 2014, 134, 657.

[20] Ault K.A., Future II Study Group: “Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials”. Lancet, 2007, 369, 1861.

[21] AIRTUM, Italian Association of Cancer Registries: “ITACAN: Cancer in Italy, Version 2.0.2014, 30 Dec 14”. Available at: http://itacan.ispo.toscana.it/italian/itacan.htm.

[22] Singapore Cancer Registry. Annual Registry Report Trends in Cancer Incidence in Singapore 2009–2014”. Available at: https://http://www.nrdo.gov.sg/docs/librariesprovider3/Publications-Cancer/cancer-trends-report-2009-2013.pdf?sfvrsn=0

[23] Australian Institute of Health and Welfare (AIHW): “Australian Cancer Incidence and Mortality (ACIM) books: Ovarian cancer”. Canberra, Australia: AIHW, 2014. Available at: http://www.aihw. gov.au/acim-books.

[24] Collaborative Group on Epidemiological Studies of Ovarian C., Beral V., Doll R., Hermon C., Peto R., Reeves G.: “Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls”. Lancet, 2008, 371, 303.

[25] Arora R.S., Alston R.D., Eden T.O., Geraci M., Birch J.M.: “Comparative incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 1979 to 2003”. Cancer, 2012, 118, 4290.

[26] Reade C.J., Riva J.J., Busse J.W., Goldsmith C.H., Elit L.: “Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis”. Gynecol. Oncol., 2013, 130, 674.

[27] Menon U., Gentry-Maharaj A., Hallett R., Ryan A., Burnell M., Sharma A., et al.: “Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)”. Lancet Oncol., 2009, 10, 327.

[28] Buys S.S., Partridge E., Black A., Johnson C.C., Lamerato L., Isaacs C., et al.: “Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial”. JAMA, 2011, 305, 2295.

[29] Sharma A., Gentry-Maharaj A., Burnell M., Fourkala E.O., Campbell S., Amso N., et al.: “Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study”. BJOG, 2012, 119, 207.

[30] Sharma A., Apostolidou S., Burnell M., Campbell S., Habib M., Gentry- Maharaj A., et al: “Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS)”. Ultrasound Obstet. Gynecol., 2012, 40, 338.

[31] Lu K.H., Skates S., Hernandez M.A., Bedi D., Bevers T., Leeds L., et al: “A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value”. Cancer, 2013, 119, 3454.

[32] Rosenthal A.N.: “Ovarian cancer screening in the high-risk population— the UK Familial Ovarian Cancer Screening Study (UKFOCSS)”. Int. J. Gynecol. Cancer, 2012, 22, S27.

[33] Morelli M., Venturella R., Mocciaro R., Di Cello A., Rania E., Lico D., et al: “Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere”. Gynecol. Oncol., 2013, 129, 448.

[34] McAlpine J.N., Hanley G.E., Woo M.M., Tone A.A., Rozenberg N., Swenerton K.D., et al: “Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention”. Am. J. Obstet. Gynecol., 2014, 210, 471 e1.

[35] Kwon J.S., McAlpine J.N., Hanley G.E., Finlayson S.J., Cohen T., Miller D.M., et al.: “Costs and Benefits of Opportunistic Salpingectomy as an Ovarian Cancer Prevention Strategy”. Obstet. Gynecol., 2015, 125, 338.

[36] “Committee opinion no. 620: salpingectomy for ovarian cancer prevention”. Obstet. Gynecol., 2015, 125, 279.

[37] Kurman R.J., Shih Ie M.: “The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory”. Am. J. Surg. Pathol., 2010, 34, 433.

[38] Bray F., Dos Santos Silva I., Moller H., Weiderpass E.: “Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention”. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 1132.

[39] Canadian Cancer Society’s Advisory Committee on Cancer Statistics: “Canadian Cancer Statistics 2014”. Available at: http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statisticspublication/?region=bc.

[40] Hong Kong Cancer Registry: “Statistics report Hong Kong: Hospital Authority, 2014”. Available at: http://www3.ha.org.hk/cancereg/publication.html.

[41] Australian Institute of Health and Welfare (AIHW): “Australian Cancer Incidence and Mortality (ACIM) books: Uterine cancer. Canberra, Australia: AIHW, 2014”. Available at: http://www.aihw.gov.au/acim-books.

[42] Public Health England Knowledge and Intelligence Team (East Midlands), National Cancer Intelligence Network (NCIN): “Outline of Uterine Cancer in the United Kingdom: Incidence, Mortality and Survival”. Sheffield and London, United Kingdom: 2013.

[43] Moline J., Mahdi H., Yang B., Biscotti C., Roma A.A., Heald B., et al.: “Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center”. Gynecol. Oncol., 2013, 130, 121.

[44] Batte B.A., Bruegl A.S., Daniels M.S., Ring K.L., Dempsey K.M., Djordjevic B., et al: “Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome”. Gynecol. Oncol., 2014, 134, 319.

[45] National Comprehensive Cancer Network (NCCN): “Clinical Practice Guidelines in Oncology”, Uterine neoplasms, 2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

[46] Kwon J.S., Scott J.L., Gilks C.B., Daniels M.S., Sun C.C., Lu K.H.: “Testing women with endometrial cancer to detect Lynch syndrome”. J. Clin. Oncol., 2011, 29, 2247.

[47] Helder-Woolderink J.M., De Bock G.H., Sijmons R.H., Hollema H., Mourits M.J.: “The additional value of endometrial sampling in the early detection of endometrial cancer in women with Lynch syndrome”. Gynecol. Oncol., 2013, 131, 304.

[48] Lecuru F., Huchon C., Metzger U., Bats A.S., Le Frere Belda M.A., Olschwang S., et al.: “Contribution of ultrasonography to endometrial cancer screening in patients with hereditary nonpolyposis colorectal cancer/Lynch syndrome”. Int. J. Gynecol. Cancer, 2010, 20, 583.

[49] Nebgen D.R., Lu K.H., Rimes S., Keeler E., Broaddus R., Munsell M.F., et al.: “Combined colonoscopy and endometrial biopsy cancer screening results in women with Lynch syndrome”. Gynecol Oncol, 2014, 135, 85-9.

[50] Manchanda R., Saridogan E., Abdelraheim A., Johnson M., Rosenthal A.N., Benjamin E., et al.: “Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS)”. Arch. Gynecol. Obstet., 2012, 286, 1555.

[51] Lu K.H., Loose D.S., Yates M.S., Nogueras-Gonzalez G.M., Munsell M.F., Chen L.M., et al.: “Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depoprovera for prevention of endometrial cancer in women with Lynch syndrome”. Cancer Prev Res (Phila.), 2013, 6, 774.

[52] Schmeler K.M., Lynch H.T., Chen L.M., Munsell M.F., Soliman P.T., Clark M.B., et al.: “Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome”. N. Engl. J. Med., 2006, 354, 261-9.